Nature Communications (Jan 2019)
Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators
- Daniel Aird,
- Teng Teng,
- Chia-Ling Huang,
- Ermira Pazolli,
- Deepti Banka,
- Kahlin Cheung-Ong,
- Cheryl Eifert,
- Craig Furman,
- Zhenhua Jeremy Wu,
- Michael Seiler,
- Silvia Buonamici,
- Peter Fekkes,
- Craig Karr,
- James Palacino,
- Eunice Park,
- Peter G. Smith,
- Lihua Yu,
- Yoshiharu Mizui,
- Markus Warmuth,
- Agustin Chicas,
- Laura Corson,
- Ping Zhu
Affiliations
- Daniel Aird
- H3 Biomedicine, Inc.
- Teng Teng
- H3 Biomedicine, Inc.
- Chia-Ling Huang
- H3 Biomedicine, Inc.
- Ermira Pazolli
- H3 Biomedicine, Inc.
- Deepti Banka
- H3 Biomedicine, Inc.
- Kahlin Cheung-Ong
- H3 Biomedicine, Inc.
- Cheryl Eifert
- H3 Biomedicine, Inc.
- Craig Furman
- H3 Biomedicine, Inc.
- Zhenhua Jeremy Wu
- H3 Biomedicine, Inc.
- Michael Seiler
- H3 Biomedicine, Inc.
- Silvia Buonamici
- H3 Biomedicine, Inc.
- Peter Fekkes
- H3 Biomedicine, Inc.
- Craig Karr
- H3 Biomedicine, Inc.
- James Palacino
- H3 Biomedicine, Inc.
- Eunice Park
- H3 Biomedicine, Inc.
- Peter G. Smith
- H3 Biomedicine, Inc.
- Lihua Yu
- H3 Biomedicine, Inc.
- Yoshiharu Mizui
- H3 Biomedicine, Inc.
- Markus Warmuth
- H3 Biomedicine, Inc.
- Agustin Chicas
- H3 Biomedicine, Inc.
- Laura Corson
- H3 Biomedicine, Inc.
- Ping Zhu
- H3 Biomedicine, Inc.
- DOI
- https://doi.org/10.1038/s41467-018-08150-5
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 15
Abstract
Small molecule modulators of RNA splicing have therapeutic potential in tumours bearing spliceosome mutations. Here, the authors identify BCL2 genes have differential sensitivities to SF3b-targeting splicing modulators and combination of SF3b-targeting splicing modulators and BCLxL inhibition induces synergistic cytotoxicity in cancer cells.
